Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8529142 | 1.00 | CYP2D6 (0.49) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| SCHEMBL355959 | 1.00 | CYP2D6 (0.49) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| Hydrochloric Acid SCHEMBL8686514 | 0.99 | CYP2D6 (0.48) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| SCHEMBL14201833 | 0.87 | CYP2D6 (0.48) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| SCHEMBL7591201 | 0.87 | CYP2D6 (0.62) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| SCHEMBL7591195 | 0.87 | CYP2D6 (0.62) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| Hydrochloric Acid SCHEMBL8014032 | 0.86 | CYP2D6 (0.60) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| Hydrochloric Acid SCHEMBL8014025 | 0.86 | CYP2D6 (0.60) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| SCHEMBL13305025 | 0.84 | CYP2D6 (0.48) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 | |
| SCHEMBL7045165 | 0.84 | CYP2D6 (0.48) | CYP2D6ALDH1A1CYP2C19HSD17B10AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311842-A1 | Use of 1-Phenyl-3-dimethylamino-propane Compounds for Treating Neuropathic Pain | GRUENENTHAL GMBH (DE) | 2010-12-09 | — | — | US | claimed |
| US-20100280128-A1 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain | GRUENENTHAL GMBH (DE) | 2010-11-04 | — | — | US | claimed |
| EP-2117525-A1 | USE OF 1-PHENYL-3-DIMETHYLAMINO-PROPANE COMPOUNDS FOR THE THERAPY OF NEUROPATHY PAIN | Grünenthal GmbH (DE) | 2009-11-18 | — | — | EP | claimed |
| WO-2008110323-A1 | USE OF 1-PHENYL-3-DIMETHYLAMINO-PROPANE COMPOUNDS FOR THE THERAPY OF NEUROPATHY PAIN | Grünenthal GmbH (DE) | 2008-09-18 | — | — | WO | claimed |
| EP-1438034-B1 | USE OF 1-PHENYL-3-DIMETHYLAMINOPROPANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2008-07-30 | — | — | EP | claimed |
| EP-1429754-B1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2008-01-16 | — | — | EP | claimed |
| EP-1562567-A1 | COMBINATION OF SELECTED ANALGESICS AND COX-II INHIBITORS | Grünenthal GmbH (DE) | 2005-08-17 | — | — | EP | claimed |
| US-20050137194-A1 | Combination of selected opioids with other active compounds for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2005-06-23 | — | — | US | claimed |
| EP-1507520-A1 | COMBINATION OF SELECTED OPIOIDS WITH OTHER ACTIVE SUBSTANCES FOR USE IN THE THERAPY OF URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2005-02-23 | — | — | EP | claimed |
| US-6841575-B2 | Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2005-01-11 | — | — | US | claimed |
| US-20040242617-A1 | active at very low doses, therefore low side effect profile | GRUENENTHAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| EP-1438034-A2 | USE OF 1-PHENYL-3-DIMETHYLAMINOPROPANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2004-07-21 | — | — | EP | claimed |
| EP-1429754-A1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2004047823-A1 | COMBINATION OF SELECTED ANALGESICS AND COX-II INHIBITORS | Grünenthal GmbH (DE) | 2004-06-10 | — | — | WO | claimed |
| US-20040034105-A1 | Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2004-02-19 | — | — | US | claimed |
| WO-2003099268-A1 | COMBINATION OF SELECTED OPIOIDS WITH OTHER ACTIVE SUBSTANCES FOR USE IN THE THERAPY OF URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2003-12-04 | — | — | WO | claimed |
| WO-2003024444-A1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2003-03-27 | — | — | WO | claimed |
| WO-2002043715-A2 | USE OF 1-PHENYL-3-DIMETHYLAMINOPROPANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2002-06-06 | — | — | WO | claimed |
| EP-3241550-B1 | (1R, 2R)-3-(DIMENTHYL AMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL FOR TREATING PAINFUL INFLAMMATIONS | GRUENENTHAL GMBH (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-0693475-A1 | 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity | Grünenthal GmbH (DE) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242617-A1 | active at very low doses, therefore low side effect profile | OPRM1, OPRK1, OPRD1 | CYP2D6 808/4885ALDH1A1 508/4885CYP2C19 1431/4885 |
| US-20040034105-A1 | Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence | PNMT, UROD, PDE3A | CYP2D6 2039/4885ALDH1A1 32/4885CYP2C19 2940/4885 |
| US-20050137194-A1 | Combination of selected opioids with other active compounds for treatment of urinary incontinence | OPRM1, OPRK1, OPRL1 | CYP2D6 552/4885ALDH1A1 257/4885CYP2C19 1468/4885 |
| US-20100280128-A1 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain | OPRK1, DRG1, OPRL1 | CYP2D6 1801/4885ALDH1A1 185/4885CYP2C19 4080/4885 |
| US-20100311842-A1 | Use of 1-Phenyl-3-dimethylamino-propane Compounds for Treating Neuropathic Pain | PMP22, GAP43, IAPP | CYP2D6 2870/4885ALDH1A1 598/4885CYP2C19 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.